Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 1/20 | 0.52 |
| ▸ | HRH1 | P35367 | 2/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 6/20 | 0.41 |
| ▸ | TLR8 | Q9NR97 | 3/20 | 0.41 |
| ▸ | MPO | P05164 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | CASP1 | P29466 | 1/20 | 0.39 |
| ▸ | CASP7 | P55210 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30498596 | 0.93 | SIGMAR1 (0.43) | MAOASIGMAR1TAAR1TLR8MPO | |
| SCHEMBL5928190 | 0.93 | SIGMAR1 (0.43) | MAOASIGMAR1TAAR1TLR8MPO | |
| SCHEMBL23159850 | 0.91 | ALOX15 (0.47) | MAOASIGMAR1TAAR1TLR8CYP3A4 | |
| Decylamine SCHEMBL27326498 | 0.89 | TLR8 (0.54) | TLR8 | |
| SCHEMBL23159817 | 0.88 | SIGMAR1 (0.46) | MAOASIGMAR1TAAR1CYP3A4ALOX15 | |
| SCHEMBL3680377 | 0.85 | MAOA (0.61) | MAOAHRH1TAAR1MPOSLC6A4 | |
| SCHEMBL23159894 | 0.85 | ALOX15 (0.47) | SIGMAR1TAAR1CYP3A4ALOX15CASP1 | |
| SCHEMBL6004011 | 0.83 | SIGMAR1 (0.46) | SIGMAR1TAAR1CYP3A4ALOX15CASP1 | |
| SCHEMBL30929931 | 0.83 | SIGMAR1 (0.46) | SIGMAR1TAAR1CYP3A4ALOX15CASP1 | |
| SCHEMBL26077417 | 0.83 | MAOA (0.58) | MAOAHRH1TAAR1TLR8MPO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11307183-B2 | Methods for determination of polar pesticides by chromatography | WATERS TECHNOLOGIES CORPORATION (US) | 2022-04-19 | — | — | US | disclosed |
| US-10167266-B2 | Sodium channel blockers | PARION SCIENCES, INC. (US) | 2019-01-01 | — | — | US | disclosed |
| US-20170267650-A1 | SODIUM CHANNEL BLOCKERS | PARION SCIENCES, INC. (US) | 2017-09-21 | — | — | US | disclosed |
| US-20150376146-A1 | SODIUM CHANNEL BLOCKERS | PARION SCIENCES, INC. (US) | 2015-12-31 | — | — | US | disclosed |
| US-8846688-B2 | Sodium channel blockers | PARION SCIENCES, INC. (US) | 2014-09-30 | — | — | US | disclosed |
| US-20140179625-A1 | SODIUM CHANNEL BLOCKERS | PARION SCIENCES, INC. (US) | 2014-06-26 | — | — | US | disclosed |
| US-20130012692-A1 | SODIUM CHANNEL BLOCKERS | PARION SCIENCES, INC. (US) | 2013-01-10 | — | — | US | disclosed |
| US-8227474-B2 | Sodium channel blockers | PARION SCIENCES, INC. (US) | 2012-07-24 | — | — | US | disclosed |
| US-8198286-B2 | Sodium channel blockers | PARION SCIENCES, INC. (US) | 2012-06-12 | — | — | US | disclosed |
| EP-1485360-B1 | SODIUM CHANNEL BLOCKERS | PARION SCIENCES INC (US) | 2011-08-17 | — | — | EP | disclosed |
| US-20040204425-A1 | Such as 4-(4-hydroxyphenyl)butylamidino-3,5-diamino-6-chloropyrazinecarboxamide hydrochloride; time-release agents; for therapy of chronic bronchitis, emphysema, cystic fibrosis, and eye disorders | PARION SCIENCES, INC. (US) | 2004-10-14 | — | — | US | disclosed |
| US-20040198749-A1 | Broncholdilator agents; hydration of mucous membranes; respiratory system disorders | PARION SCIENCES, INC. | 2004-10-07 | — | — | US | disclosed |
| US-20040198748-A1 | Antihistamines; bronchodilators; antiinflammatory agents; inflammatory bowel disorders | PARION SCIENCES, INC. | 2004-10-07 | — | — | US | disclosed |
| US-20030199456-A1 | Treating diseases characterized by too little liquid on mucosal surfaces using a\"topical\" sodium channel blocker designed to increased potency, reduced mucosal absorption, and slow dissociation; 2,6-diaminopyrazine derivatives | CYFI, INC. (US) | 2003-10-23 | — | — | US | disclosed |
| WO-2003070182-A2 | SODIUM CHANNEL BLOCKERS | JOHNSON MICHAEL R (US) | 2003-08-28 | — | — | WO | disclosed |
| US-20020032262-A1 | 2-aminoarylmethylamine solid support templated for preparation of highly functionalized heterocycle compounds | ZHANG JINFANG (US) | 2002-03-14 | — | — | US | disclosed |
| US-4496567-A | HSITAMINE H2 ANTAGONISTS | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1985-01-29 | — | — | US | disclosed |
| EP-0013071-B1 | PYRIMIDINONE DERIVATIVES, PROCESSES FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1983-11-16 | — | — | EP | disclosed |
| EP-0013071-A1 | Pyrimidinone derivatives, processes for preparing them and pharmaceutical compositions containing them | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1980-07-09 | — | — | EP | disclosed |
| WO-1980000966-A1 | NEW HISTAMINE H2-ANTAGONISTS | SMITH KLINE FRENCH LAB (GB) | 1980-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170267650-A1 | SODIUM CHANNEL BLOCKERS | HCN4, SCN2B, SCN5A | MAOA 1356/4885HRH1 1825/4885SIGMAR1 1415/4885 |
| US-10167266-B2 | Sodium channel blockers | SCNN1B, SCNN1A, SCNN1G | MAOA 2060/4885HRH1 665/4885SIGMAR1 1538/4885 |
| US-20150376146-A1 | SODIUM CHANNEL BLOCKERS | HCN4, SCN2B, SCN5A | MAOA 1356/4885HRH1 1825/4885SIGMAR1 1415/4885 |
| US-20140179625-A1 | SODIUM CHANNEL BLOCKERS | HCN4, SCN2B, SCN5A | MAOA 1356/4885HRH1 1825/4885SIGMAR1 1415/4885 |
| US-20040204425-A1 | Such as 4-(4-hydroxyphenyl)butylamidino-3,5-diamino-6-chloropyrazinecarboxamide hydrochloride; time-release agents; for therapy of chronic bronchitis, emphysema, cystic fibrosis, and eye disorders | CFTR, TRPC4, TRPC5 | MAOA 1479/4885HRH1 229/4885SIGMAR1 3046/4885 |
| US-20040198749-A1 | Broncholdilator agents; hydration of mucous membranes; respiratory system disorders | AQP1, TRPV1, AQP3 | MAOA 2372/4885HRH1 174/4885SIGMAR1 2011/4885 |
| US-20130012692-A1 | SODIUM CHANNEL BLOCKERS | HCN4, SCN2B, SCN5A | MAOA 1356/4885HRH1 1825/4885SIGMAR1 1415/4885 |
| US-20030199456-A1 | Treating diseases characterized by too little liquid on mucosal surfaces using a\"topical\" sodium channel blocker designed to increased potency, reduced mucosal absorption, and slow dissociation; 2,6-diaminopyrazine derivatives | SCNN1B, KCNN2, KCNN1 | MAOA 1540/4885HRH1 787/4885SIGMAR1 1426/4885 |
| US-20040198748-A1 | Antihistamines; bronchodilators; antiinflammatory agents; inflammatory bowel disorders | HRH4, HRH2, HRH1 | MAOA 842/4885HRH1 3/4885SIGMAR1 417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.